



Press Release

Poxel to Present New Imeglimin Data Demonstrating Beta Cell Function Preservation at the 14th Annual World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease

Lyon, France, November 21, 2016 – POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative drugs to treat type 2 diabetes, today announced that an Imeglimin abstract has been accepted for a poster presentation and oral presentation at the 14th Annual World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC), which is being held on December 1-3, 2016, at the Hilton Universal City Hotel in Los Angeles, California.

Imeglimin Poster Information

Poster # 00084

Title: “*Imeglimin Preserves Beta Cell Function and Mass in Male Zucker Diabetic Fatty Rats*”

Session Name: 2016 Poster Session of the WCIRDC

Date, Time & Location: Thursday, December 1, 2016, at 12:15-1:30 PM and 7:30-8:30 PM PT, Ballroom AB

Imeglimin Oral Presentation Information

Title: “*Imeglimin Preserves Beta Cell Function and Mass in Male Zucker Diabetic Fatty Rats (#00084)*”

Session Name: Abstract Oral Presentation Session

Date, Time & Location: Friday, December 2, 2016, at 6:30-8:00 PM PT, ‘HIRO’ room located at the Lobby Level

Poxel will announce the results through a press release after the poster presentation.

About Imeglimin

Imeglimin is the first in a new chemical class of oral anti-diabetic agents, the Glimins. Imeglimin acts on the three main target organs involved in glucose homeostasis: the liver, muscle, and the pancreas. Imeglimin has a unique mechanism of action that targets mitochondrial bioenergetics. This has the potential for glucose lowering benefits, as well as the potential to prevent endothelial dysfunction, which can provide protective effects on micro- and macro-vascular defects induced by diabetes, and benefits on beta cell protection and function, which can delay disease progression. This distinct mode of action compared to existing treatments for type 2 diabetes makes Imeglimin a prime candidate in monotherapy and to complement other treatments such as metformin or sitagliptin.



Imeglimin has completed Phase 2 development in over 850 subjects in the US and EU and is currently being studied in a 300-patient Phase 2b clinical trial in Japan.

About Poxel SA

Poxel uses its development expertise in metabolism to advance a pipeline of drug candidates focused on the treatment of type 2 diabetes. We have successfully completed our Phase 2 clinical program for our first-in-class lead product, Imeglimin, which targets mitochondrial dysfunction, in the U.S. and EU and have fully enrolled a Phase 2b clinical study in Japan. Our second program, PXL770, a direct AMPK activator, is in Phase 1 development. We intend to generate further growth through strategic partnerships and pipeline development. Euronext: POXEL, www.poxel.com

Contacts

Poxel SA

Jonae R. Barnes
Senior Vice President, IR and Public Relations
jonae.barnes@poxelpharma.com
+1 617 818 2985

Investor Relations / Media - Europe/US

MacDougall Biomedical Communications
Gretchen Schweitzer ou Stephanie May
smay@macbiocom.com
+ 49 89 2424 3494 or + 49 175 571 1562

Investor Relations / Media - France

NewCap
Florent Alba / Nicolas Merigeau
poxel@newcap.fr
+ 33 1 44 71 98 55